ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
18.63 21.58 23.73 27.90

+8 more quarters

P/S ratio
5.02 5.89 6.51 7.61
P/FCF ratio
17.41 18.79 19.77 22.78
P/Operating CF
62.38 58.88 103.40 87.50
P/B ratio
4.31 5.03 5.56 6.54
EV/Sales
4.83 5.66 6.32 7.43
EV/EBITDA
12.81 14.55 16.52 19.67
EV/FCF
16.76 18.07 19.20 22.22
Current Ratio
3.10 3.01 3.06 2.89
Net Debt/EBITDA
(2.12) (2.21) (1.83) (1.93)
Debt/Equity
0.06 0.06 0.06 0.07
Earnings Yield
5.37% 4.63% 4.21% 3.58%
Free Cash Flow Yield
5.74% 5.32% 5.06% 4.39%
Free Cash Flow per Share
2.73 3.54 2.09 2.82
Book value per Share
45.25 44.67 43.34 41.87
Free Cash Flow
397.38 514.54 305.19 411.54
EV/EBIT
14.46 16.58 18.76 22.38
Other line items

Show all line items

Columns are period end dates